https://www.nasdaq.com/press-release/alkermes-to-take-part-in-the-40th-annual-j.p.-morgan-healthcare-conference-2022-01-05
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-the-fourth-annual-evercore-isi-healthconx-conference-2021-11
https://www.nasdaq.com/press-release/alkermes-announces-the-appointment-of-cato-t.-laurencin-m.d.-ph.d.-to-its-board-of
https://www.nasdaq.com/press-release/alkermes-announces-first-subject-dosed-in-phase-1-study-of-alks-1140-for-the
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-the-stifel-virtual-healthcare-conference-2021-11-09
https://www.nasdaq.com/press-release/alkermes-announces-receipt-of-notices-of-partial-termination-from-janssen
https://www.nasdaq.com/press-release/alkermes-to-present-data-on-nemvaleukin-alfa-at-the-society-for-immunotherapy-of
https://www.nasdaq.com/press-release/alkermes-to-present-new-research-from-psychiatry-and-addiction-portfolios-at-upcoming
https://www.nasdaq.com/press-release/alkermes-plc-reports-third-quarter-2021-financial-results-2021-10-27
https://www.nasdaq.com/press-release/alkermes-initiates-artistry-7-phase-3-trial-of-nemvaleukin-alfa-in-patients-with
https://www.nasdaq.com/press-release/alkermes-receives-fda-fast-track-designation-for-nemvaleukin-alfa-in-combination-with
https://www.nasdaq.com/press-release/alkermes-to-report-third-quarter-2021-financial-results-on-oct.-27-2021-2021-10-20
https://www.nasdaq.com/press-release/alkermes-announces-commercial-availability-of-lybalvir-for-the-treatment-of
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-the-cantor-virtual-global-healthcare-conference-2021-09-22
https://www.nasdaq.com/press-release/new-survey-provides-insights-into-drinking-behaviors-during-the-pandemic-2021-09-22
https://www.nasdaq.com/press-release/alkermes-to-present-two-posters-on-investigational-immuno-oncology-candidate
https://www.nasdaq.com/press-release/alkermes-announces-launch-of-4th-annual-alkermes-pathways-research-awardsr-program
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-the-citi-annual-biopharma-virtual-conference-2021-09-02
https://www.nasdaq.com/press-release/alkermes-receives-fda-fast-track-designation-for-nemvaleukin-alfa-for-the-treatment
https://www.nasdaq.com/press-release/alkermes-plc-reports-second-quarter-2021-financial-results-2021-07-28
https://www.nasdaq.com/press-release/alkermes-announces-recipients-of-2021-alkermes-inspiration-grantsr-program-2021-07-0
https://www.nasdaq.com/press-release/alkermes-announces-recipients-of-2021-alkermes-inspiration-grantsr-program-2021-07-23
https://www.nasdaq.com/press-release/questions-to-consider-asking-your-hcp-about-alcohol-dependence-2021-07-22
https://www.nasdaq.com/press-release/alkermes-to-report-second-quarter-2021-financial-results-on-july-28-2021-2021-07-21
https://www.nasdaq.com/press-release/alkermes-presented-new-data-analysis-on-healthcare-resource-use-among-veterans-with-0
https://www.nasdaq.com/press-release/alkermes-presented-new-data-analysis-on-healthcare-resource-use-among-veterans-with
https://www.nasdaq.com/press-release/alkermes-announces-former-professional-baseball-player-cc-sabathia-as-spokesperson-0
https://www.nasdaq.com/press-release/alkermes-announces-former-professional-baseball-player-cc-sabathia-as-spokesperson
https://www.nasdaq.com/press-release/alkermes-presents-new-data-on-nemvaleukin-alfa-at-2021-american-society-of-clinical
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-the-goldman-sachs-annual-global-healthcare-conference-2021
https://www.nasdaq.com/press-release/alkermes-announces-fda-approval-of-lybalvitm-for-the-treatment-of-schizophrenia-and
https://www.nasdaq.com/press-release/alkermes-to-host-webcast-with-expert-oncologist-panel-to-discuss-data-on-nemvaleukin
https://www.nasdaq.com/press-release/alkermes-announces-the-appointment-of-emily-peterson-alva-to-its-board-of-directors
https://www.nasdaq.com/press-release/alkermes-announces-2021-alkermes-inspiration-grantsr-program-to-support-innovative
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-the-bofa-securities-2021-virtual-healthcare-conference-2021
https://www.nasdaq.com/press-release/alkermes-to-showcase-data-from-psychiatry-portfolio-at-upcoming-scientific
https://www.nasdaq.com/press-release/alkermes-announces-agreement-with-sarissa-capital-2021-04-30
https://www.nasdaq.com/press-release/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society
https://www.nasdaq.com/press-release/alkermes-plc-reports-first-quarter-2021-financial-results-2021-04-28
https://www.nasdaq.com/press-release/alkermes-launches-new-disease-state-website-to-offer-education-about-alcohol
https://www.nasdaq.com/press-release/alkermes-initiates-artistry-6-trial-of-nemvaleukin-alfa-monotherapy-in-patients-with
https://www.nasdaq.com/press-release/alkermes-to-host-conference-call-to-discuss-first-quarter-2021-financial-results-2021
https://www.nasdaq.com/press-release/alkermes-presents-new-data-from-psychiatry-portfolio-at-virtual-2021-congress-of-the
https://www.nasdaq.com/press-release/alkermes-announces-clinical-trial-collaboration-and-supply-agreement-with-msd-to
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-stifels-3rd-annual-cns-day-2021-03-25
https://www.nasdaq.com/press-release/alkermes-investor-day-to-focus-on-scientific-progress-and-value-creation-strategy
https://www.nasdaq.com/press-release/alkermes-announces-fda-orphan-drug-designation-for-nemvaleukin-alfa-for-treatment-of
https://www.nasdaq.com/press-release/alkermes-to-hold-virtual-investor-day-2021-03-04
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-svb-leerink-10th-annual-global-healthcare-conference-2021-02
https://www.nasdaq.com/press-release/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec.-0
https://www.nasdaq.com/press-release/alkermes-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2020
https://www.nasdaq.com/press-release/nida-funded-study-evaluating-extended-release-injectable-naltrexone-plus-bupropion
https://www.nasdaq.com/press-release/alkermes-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference-2021-01-06
https://www.nasdaq.com/press-release/alkermes-announces-updates-to-executive-leadership-team-2021-01-06
https://www.nasdaq.com/press-release/fda-accepts-alkermes-resubmission-of-new-drug-application-for-alks-3831-2020-12-29
https://www.nasdaq.com/press-release/alkermes-announces-strategic-value-enhancement-plan-and-continued-board-refreshment
https://www.nasdaq.com/press-release/alkermes-receives-fda-complete-response-letter-related-to-alks-3831-manufacturing
https://www.nasdaq.com/press-release/alkermes-presents-new-data-on-alks-4230-at-society-for-immunotherapy-of-cancers-sitc
https://www.nasdaq.com/press-release/alkermes-reschedules-third-quarter-2020-financial-results-conference-call-to-10%3a30-a
https://www.nasdaq.com/press-release/alkermes-plc-reports-third-quarter-2020-financial-results-and-raises-2020-financial
https://www.nasdaq.com/press-release/alkermes-to-host-conference-call-to-discuss-third-quarter-2020-financial-results-2020
https://www.nasdaq.com/press-release/fda-advisory-committee-votes-in-support-of-alks-3831-for-the-treatment-of
https://www.nasdaq.com/press-release/trading-in-alkermes-ordinary-shares-halted-today-2020-10-09
https://www.nasdaq.com/press-release/alkermes-announces-posting-of-briefing-documents-for-fda-advisory-committee-meeting
https://www.nasdaq.com/press-release/alkermes-presents-new-clinical-data-on-alks-4230-in-mini-oral-presentation-at-2020
https://www.nasdaq.com/press-release/alkermes-presents-new-psychiatry-data-at-psych-congress-2020-virtual-experience-2020
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-cantor-virtual-global-healthcare-conference-2020-09-09
https://www.nasdaq.com/press-release/alkermes-to-present-new-data-on-investigational-immuno-oncology-candidate-alks-4230
https://www.nasdaq.com/press-release/virtual-fda-advisory-committee-meeting-to-review-new-drug-application-for-alks-3831
https://www.nasdaq.com/press-release/alkermes-initiates-phase-2-study-designed-to-evaluate-clinical-and-immunologic
https://www.nasdaq.com/press-release/american-journal-of-psychiatry-publishes-data-from-alkermes-phase-3-enlighten-2
https://www.nasdaq.com/press-release/alkermes-plc-reports-second-quarter-2020-financial-results-and-issues-2020-financial
https://www.nasdaq.com/press-release/alkermes-to-host-conference-call-to-discuss-second-quarter-2020-financial-results
https://www.nasdaq.com/press-release/alkermes-announces-launch-of-3rd-annual-alkermes-pathways-research-awardsr-program
https://www.nasdaq.com/press-release/alkermes-awards-covid-19-relief-fund-grants-to-10-innovative-programs-designed-to
https://www.nasdaq.com/press-release/new-preclinical-data-on-alks-4230-in-combination-with-lucitanib-to-be-presented-at
https://www.nasdaq.com/press-release/alkermes-to-take-part-in-41st-annual-goldman-sachs-global-healthcare-conference-2020
https://www.nasdaq.com/press-release/alkermes-highlights-new-data-from-schizophrenia-portfolio-at-the-american-society-of
https://www.nasdaq.com/press-release/journal-of-clinical-psychiatry-publishes-data-from-alkermes-alpine-study-in-patients
https://www.nasdaq.com/press-release/alkermes-presents-new-data-from-schizophrenia-portfolio-at-virtual-2020-congress-of
https://www.nasdaq.com/press-release/alkermes-announces-expansion-of-patient-services-and-provider-network-to-support
https://www.nasdaq.com/press-release/alkermes-announces-upcoming-presentation-at-the-bank-of-america-securities-virtual
https://www.nasdaq.com/press-release/alkermes-launches-covid-19-relief-fund-to-support-innovative-programs-helping
https://www.nasdaq.com/press-release/alkermes-plc-reports-first-quarter-2020-financial-results-and-provides-covid-19
https://www.nasdaq.com/press-release/alkermes-to-host-conference-call-to-discuss-first-quarter-2020-financial-results-2020
https://www.nasdaq.com/press-release/alkermes-announces-publication-of-preclinical-data-for-alks-4230-in-the-journal-for
https://www.nasdaq.com/press-release/journal-of-clinical-psychiatry-publishes-data-from-alkermes-phase-3-enlighten-1
https://www.nasdaq.com/press-release/alkermes-corporate-presentation-to-be-webcast-at-the-cowen-and-company-40th-annual
https://www.nasdaq.com/press-release/alkermes-to-present-at-the-9th-annual-svb-leerink-global-healthcare-conference-2020
https://www.nasdaq.com/press-release/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec.-31
https://www.nasdaq.com/press-release/alkermes-to-host-conference-call-to-discuss-fourth-quarter-and-year-end-2019
https://www.nasdaq.com/press-release/alkermes-announces-u.s.-food-and-drug-administration-acceptance-of-alks-3831-new-drug
https://www.nasdaq.com/press-release/alkermes-corporate-presentation-to-be-webcast-at-the-38th-annual-j.p.-morgan
https://www.nasdaq.com/press-release/alkermes-to-present-at-the-evercore-isi-2nd-annual-healthconx-conference-2019-11-26
https://www.nasdaq.com/press-release/alkermes-completes-acquisition-of-rodin-therapeutics-2019-11-25
https://www.nasdaq.com/press-release/alkermes-submits-new-drug-application-to-u.s.-food-and-drug-administration-for-alks
https://www.nasdaq.com/press-release/alkermes-to-acquire-rodin-therapeutics-2019-11-18
https://www.nasdaq.com/press-release/alkermes-corporate-presentation-to-be-webcast-at-upcoming-healthcare-conferences-2019
https://www.nasdaq.com/press-release/alkermes-announces-receipt-of-%24150-million-milestone-payment-from-biogen-related-to
https://www.nasdaq.com/press-release/alkermes-announces-new-data-from-alks-4230-clinical-development-program-at-society
https://www.nasdaq.com/press-release/alkermes-to-present-data-from-alks-4230-clinical-development-program-at-the-society
https://www.nasdaq.com/press-release/biogen-and-alkermes-announce-fda-approval-of-vumeritytm-diroximel-fumarate-for
https://www.nasdaq.com/press-release/alkermes-plc-reports-third-quarter-2019-financial-results-and-implementation-of
https://www.nasdaq.com/press-release/alkermes-announces-clinical-collaboration-with-fred-hutchinson-cancer-research-center
https://www.nasdaq.com/press-release/alkermes-to-host-conference-call-to-discuss-third-quarter-2019-financial-results-2019
https://www.nasdaq.com/press-release/alkermes-presents-new-health-economics-and-outcomes-research-on-patients-with
https://www.nasdaq.com/press-release/alkermes-to-present-at-the-cantor-fitzgerald-global-healthcare-conference-2019-09-26
https://www.nasdaq.com/press-release/diroximel-fumarate-demonstrated-significantly-improved-gastrointestinal-tolerability
https://www.nasdaq.com/press-release/alkermes-announces-settlement-with-amneal-over-vivitrolr-patent-dispute-2019-07-29
https://www.nasdaq.com/press-release/alkermes-plc-reports-second-quarter-2019-financial-results-2019-07-25
https://www.nasdaq.com/press-release/alkermes-to-host-conference-call-to-discuss-second-quarter-2019-financial-results
https://www.nasdaq.com/press-release/alkermes-expands-planned-new-drug-application-for-alks-3831-to-include-treatment-of
https://www.nasdaq.com/press-release/alkermes-demonstrates-commitment-to-local-community-for-11th-consecutive-year-with
https://www.nasdaq.com/press-release/alkermes-advances-alks-4230-monotherapy-expansion-phase-artistry-1-patients-renal
https://www.nasdaq.com/press-release/alkermes-present-new-data-mental-health-portfolio-american-society-clinical
https://www.nasdaq.com/press-release/alkermes-present-ubs-global-healthcare-conference-2019-05-14
https://www.nasdaq.com/press-release/alkermes-plc-reports-first-quarter-2019-financial-results-2019-04-25
https://www.nasdaq.com/press-release/alkermes-appoints-industry-veteran-c-todd-nichols-senior-vice-president-sales-and
https://www.nasdaq.com/press-release/alkermes-host-conference-call-discuss-first-quarter-2019-financial-results-2019-04-18
https://www.nasdaq.com/press-release/alkermes-announces-positive-topline-results-innovative-study-aristadar-and-invega
